Metastatic uveal melanoma : A valid indication for liver resection

被引:0
作者
Hand, Fiona [1 ]
Doherty, Sadhbh [1 ]
Gullo, Giuseppe [2 ]
Geoghegan, Justin [1 ]
Crown, John [2 ]
Hoti, Emir [1 ]
机构
[1] St Vincents Univ Hosp, Dept Hepatobiliary & Liver Transplant Surg, Elm Pk, Dublin 4, Ireland
[2] St Vincents Univ Hosp, Dept Med Oncol, Elm Pk, Dublin 4, Ireland
来源
JOURNAL OF BUON | 2020年 / 25卷 / 02期
关键词
liver metastases; metastatic uveal melanoma; metastasectomy; IPILIMUMAB; SURVIVAL; CHEMOTHERAPY; PROGRESSION; SURGERY; DISEASE;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Owing to its relative resistance to chemotherapeutics, prognosis following the diagnosis of metastatic uveal melanoma has remained disappointing. On this basis, liver resection in cases of isolated hepatic metastases has been postulated as a viable treatment option. Herein we performed an analysis of patients who underwent hepatic metastatectomy for uveal melanoma and compared their outcomes to those undergoing resection for colorectal cancer liver metastases (CRLM) in the same time period. Methods: From 2008 to 2018, all patients referred to our unit with hepatic metastases were included for analysis. Performing a 3:1 matched cohort analysis, patients with metastatic uveal melanoma were matched for age, sex, operative approach, tumour number and size to those undergoing resection for CRLM. Clinicopathological data was sought from a prospectively maintained database and reviewed along with 30-day post-operative morbidity and mortality. Results: Fifteen patients underwent hepatic metastasectomy for primary uveal melanoma. A further 45 patients undergoing hepatectomy for metastatic colorectal cancer acted as the control group. No in-hospital mortality was noted with four patients (26.6%) developing post-operative morbidity. The median follow-up period following melanoma resection was 27 months (range 5-211) with 1-, 3- and 5- year overall survival for this cohort of 86.6%, 53.3% and 40%, respectively. There was no difference in overall survival between the melanoma and CRLM group (p =0.80). Conclusion: In patients presenting with hepatic metastases from uveal melanoma, this present study supports the rationale to proceed to surgery with acceptable morbidity and mortality.
引用
收藏
页码:1161 / 1165
页数:5
相关论文
共 22 条
  • [1] [Anonymous], SURG ENDOSC
  • [2] Systematic review and meta-analysis of liver resection for metastatic melanoma
    Aubin, J. -M.
    Rekman, J.
    Vandenbroucke-Menu, F.
    Lapointe, R.
    Fairfull-Smith, R. J.
    Mimeault, R.
    Balaa, F. K.
    Martel, G.
    [J]. BRITISH JOURNAL OF SURGERY, 2013, 100 (09) : 1138 - 1147
  • [3] Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
    Buder, Kristina
    Gesierich, Anja
    Gelbrich, Goetz
    Goebeler, Matthias
    [J]. CANCER MEDICINE, 2013, 2 (05): : 674 - 686
  • [4] Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma
    Caralt, Mireia
    Marti, Josep
    Cortes, Javier
    Fondevila, Constantino
    Bilbao, Itxarone
    Fuster, Josep
    Carlos Garcia-Valdecasas, Juan
    Sapisochin, Gonzalo
    Balsells, Joaquim
    Charco, Ramon
    [J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2011, 18 (02) : 268 - 275
  • [5] Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
    Carvajal, Richard D.
    Piperno-Neumann, Sophie
    Kapiteijn, Ellen
    Chapman, Paul B.
    Frank, Stephen
    Joshua, Anthony M.
    Piulats, Josep M.
    Wolter, Pascal
    Cocquyt, Veronique
    Chmielowski, Bartosz
    Evans, T. R. Jeffry
    Gastaud, Lauris
    Linette, Gerald
    Berking, Carola
    Schachter, Jacob
    Rodrigues, Manuel J.
    Shoushtari, Alexander N.
    Clemett, Delyth
    Ghiorghiu, Dana
    Mariani, Gabriella
    Spratt, Shirley
    Lovick, Susan
    Barker, Peter
    Kilgour, Elaine
    Lai, Zhongwu
    Schwartz, Gary K.
    Nathan, Paul
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1232 - +
  • [6] Metastatic disease from uveal melanoma: treatment options and future prospects
    Carvajal, Richard D.
    Schwartz, Gary K.
    Tezel, Tongalp
    Marr, Brian
    Francis, Jasmine H.
    Nathan, Paul D.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (01) : 38 - 44
  • [7] Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
    Carvajal, Richard D.
    Sosman, Jeffrey A.
    Quevedo, Jorge Fernando
    Milhem, Mohammed M.
    Joshua, Anthony M.
    Kudchadkar, Ragini R.
    Linette, Gerald P.
    Gajewski, Thomas F.
    Lutzky, Jose
    Lawson, David H.
    Lao, Christopher D.
    Flynn, Patrick J.
    Albertini, Mark R.
    Sato, Takami
    Lewis, Karl
    Doyle, Austin
    Ancell, Kristin
    Panageas, Katherine S.
    Bluth, Mark
    Hedvat, Cyrus
    Erinjeri, Joseph
    Ambrosini, Grazia
    Marr, Brian
    Abramson, David H.
    Dickson, Mark Andrew
    Wolchok, Jedd D.
    Chapman, Paul B.
    Schwartz, Gary K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (23): : 2397 - 2405
  • [8] Diener-West M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1639
  • [9] Long-term survival of uveal melanoma patients after surgery for liver metastases
    Frenkel, S.
    Nir, I.
    Hendler, K.
    Lotem, M.
    Eid, A.
    Jurim, O.
    Pe'er, J.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2009, 93 (08) : 1042 - 1046
  • [10] The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection
    Gomez, D.
    Wetherill, C.
    Cheong, J.
    Jones, L.
    Marshall, E.
    Damato, B.
    Coupland, S. E.
    Ghaneh, P.
    Poston, G. J.
    Malik, H. Z.
    Fenwick, S. W.
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (06) : 542 - 547